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Abstract Antibodies to Fas/APOl receptor induce effective 
apoptosis in WIL-2 cells of the human B-lymphoid line. 
Quantitative assessment of the extent of the death in cells 
synchronized by thymidine block revealed a significant increase 
in their sensitivity to the cytocidal effect mediated by Fas/APOl 
during the Gi phase of the cell cycle. Western analysis of the 
content of the p53 antigen in the cytoplasm and nuclei of the cells 
showed that the Fas/APOl-induced death is accompanied by 
massive translocation of the p53 from the cytoplasm to the 
nucleus. These findings suggest that cell vulnerability to the Fas/ 
APOl-mediated apoptosis is subjected to regulation by cell 
cycle-dependent mechanisms, one of which is probably the 
function of the p53 antigen. 
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1. Introduction 
Apoptosis of dividing cells has been shown to occur at 
various phases of the cell cycle depending on cell type and/ 
or the nature of a stimulus [1-5]. In general, any of inducers 
results in the disturbance of gene expression or their product 
function and it is considered to be a reason of an imbalance 
between the growth-inhibitory and the growth-promoting sig-
nals [1,6-8]. However, the mechanisms of such an interrela-
tion of cell death and proliferation are still obscure. 
The Fas/Apo-l/CD95 cell surface receptor belongs to the 
nerve growth factor/tumor necrosis factor (TNF) receptor 
family and can signal apoptosis [9-11]. Evidence has been 
presented recently for a crucial role of Fas antigen and its 
ligand in natural killer-mediated cytotoxicity, T-lymphocyte 
selection and T-cell receptor-induced apoptosis [12-16]. Fas 
has been shown to trigger death in a variety of non-lymphoid 
cell lines upon specific antibody (anti-Fas Abs) binding [3,17-
19]. In these cases usually the time of realisation of Fas-medi-
ated apoptosis (12-20 h) is comparable to the cell doubling 
time period, which is consistent with the possibility of an 
involvement of cell cycle regulatory mechanism(s) in death. 
This study was undertaken to investigate the possible cell-
cycle specificity of Fas-mediated signalling. The results indi-
cate that cells in the Gi stage are more sensitive to anti-Fas 
Abs-induced death. Such a vulnerability is perhaps related to 
the p53-dependent activation of death genes. 
2. Materials and methods 
Gi/S blockade of WIL-2 cells was achieved by incubation of cells in 
RPMI-1640 medium supplemented with 10% dialysed fetal calf serum, 
""Corresponding author. Fax: (7) (967) 790553. 
100 units/ml penicillin, 100 mg/ml streptomycin and 5 mM thymidine 
for 16 h. Then the cells were washed twice and the medium was 
replaced by RPMI-1640 with 10% FBS and antibiotics. The anti-
Fas IgM (Upstate Biotechnology, USA) were added at various time 
points after thymidine removal. Aliquots of the cells for cell cycle 
analysis and cell viability determination were taken every 3 h. To 
arrest cells in the Gi phase mimosine was added to the medium at 
a final concentration of 75 mM for 10 h [20]. After washing, at 
various time periods the WIL-2 cells were rinsed and their cell cycle 
distribution and sensitivity to the cytotoxic effect of anti-Fas antibod-
ies were determined. FACS analysis of propidium iodide-stained cells 
was used for assessment of WIL-2 cell viability [21]. The percentage of 
dead cells was calculated as follows: 
i ^ X l O O 
where C is the number of viable cells in the control sample and E in 
the sample treated with anti-Fas IgM; ( is time of treatment. 
Cell cycle was analysed as described [22]. 
The cytoplasmic and nuclear fractions from WIL-2 cells were pre-
pared by hypotonic shock as follows [23]. Control and anti-Fas Abs-
treated cells were lysed in 10 mM Tris-HCl, pH 7.5, 0.5% Nonidet P-
40, 10 mM NaCl, 1.5 mM MgCl, 1 mM PMSF and pelleted by 
centrifugation at 30000Xg for 30 min. The supernatant was collected 
and used as a cytoplasmic fraction. The nuclear fraction was extracted 
from the pellet by 10 mM Tris-HCl, pH 7.5, 1.5 mM MgCl and 0.5 M 
NaCl at 4°C for 20 min. The cytoplasmic and nuclear fractions were 
normalized for protein concentration by the method of Bradford [24] 
and analysed by Western blotting with anti-cyclin Dl, anti-c-myc 
(Santa Cruz Biotech.) and anti-p53 (a gift of Dr. P. Chumakov, In-
stitute of Molecular Biology, RAS, Moscow) antibodies followed by 
probing with horseradish peroxidase-conjugated goat anti-mouse anti-
bodies. 
3. Results and discussion 
WIL-2 cells are the suspension B lymphoblastoid cell line 
and can be induced by anti-Fas Abs to apoptosis without any 
additional sensitizing treatment. Although the dying cells re-
veal the typical morphological features of apoptosis, no inter-
nucleosomal DNA degradation is observed (data not shown). 
The absence of the soluble DNA fragments makes it easy to 
analyse the cell cycle phase of dying cells without taking spe-
cial precautions to prevent the loss of DNA contents. We 
therefore selected this particular cell line for assessing the 
relationship between the cell cycle stage and the sensitivity 
of cells to anti-Fas Abs. 
Initial attempts to synchronize the WIL-2 cells by isoleucine 
deprivation or using hydroxyurea or aminopterine as blocking 
agents were unsuccessful because of their high cytotoxicity. 
However, by thymidine arrest we did manage to reach effec-
tive synchronization manifested in synchronous entry of up to 
80% of cells to the S phase immediately after nucleoside re-
moval (Fig. 1). To make the following figures more readable 
we marked cells 0, 1.5, 3, 6 and 9 h after a cancel of blockade 
as Gi/S, S, S/G2, M/Gj and G! populations, respectively. 
Testing the effect of anti-Fas antibodies on WIL-2 cells that 
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Fig. 1. Cell cycle distribution 0, 1.5, 3, 6 and 9 h after blockade 
removal. X-axis, DNA content; Y-axis, cell number. 
were arrested at the Gi/S border with 5 mM thymidine at 
various time points after thymidine removal revealed a signifi-
cant change in their sensitivity throughout the cell cycle. It 
turned out that the extent of the specific antibody cytotoxicity 
was increased in the order Gx/S < G2 < M/Gt < 'second' Gt 
(Fig. 2). A similar picture, though less prominent, was ob-
served when anti-Fas Abs were applied at the lower concen-
tration (data not shown). There are at least two possible ex-
planations of the effects revealed. First, cells should pass the 
phase of mitosis and die afterwards; and second, cells in Gi 
are more sensitive to the cytotoxic effect of anti-Fas antibod-
ies. 
To test these suggestions the experiments were carried out 
with another blocking agent, mimosine. It is a rare amino acid 
that can arrest mammalian cells in Gi [20]. After the mimo-
sine removal cells completed the Gi stage of the cell cycle and 
entered into the S phase within 3 h. They kept the synchro-
nous movement throughout the cell cycle up to 12 h after the 
treatment, and desynchronized after mitosis (data not shown). 
Fig. 3 indicates that anti-Fas antibodies added to cells in early 
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Fig. 2. Kinetics of Fas-mediated death of WIL-2 cells at various 
stages of the cell cycle. Anti-Fas Abs were added to cells 0, 1.5, 3, 
6 and 9 h after thymidine removal, and viability was measured 
every 3 h (see Section 2). The values represent data of at least two 
independent experiments. 
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Fig. 3. Kinetics of Fas-mediated death of WIL-2 cells at various 
stages of the cell cycle. Anti-Fas Abs were added to cells 0, 3, 6, 9 
and 12 h after mimosine removal, and viability was measured every 
3 h (see Section 2). The values represent data of at least two inde-
pendent experiments. 
middle Gi induced a more prominent cytotoxicity than in 
other phases of the cell cycle. Thus, the experiments with 
two different blocking agents show that the sensitivity of 
WIL-2 cells increased the closer they were to some point in 
Gi. 
The highest cytotoxicity in Gi is obviously determined by 
an involvement of cell cycle-depending protein(s) in Fas-medi-
ated signal transduction. The Western analysis of possible 
candidates for the role of Gi-specific regulatory proteins, in 
particular cyclin Dl , p53 and c-myc proteins, did not indicate 
the alterations of their expression in the synchronized cells 
(data not shown). However, taking into account the possible 
Gi-specific redistribution of p53 [25,26], the intracellular lo-
cation of this protein was analysed. As one can see in Fig. 4, 
the bulk of p53 was revealed in the cytoplasmic fraction of 
control WIL-2 cells. The treatment with anti-Fas Abs resulted 
in the translocation of the protein into the nuclear fraction. 
One of the possible explanations is based on the assumption 
that p53 located in nuclei in Gi activates the transcription of 
genes involved in Fas-mediated cytotoxic signalling. Thus, the 
preferential cell sensitivity in Gi to anti-Fas Abs might be 
determined by the p53-dependent activation of 'cell death' 
genes. It should be noted that this explanation is valid only 
for the situation when anti-Fas-dependent cytotoxicity is ob-
served in the absence of inhibitors of RNA and protein syn-
thesis. At the same time, it cannot be excluded that p53 trans-
Fig. 4. p53 redistribution in cells treated with anti-Fas Abs. C, cyto-
plasmic fraction; N, nuclear fraction. Cells were extracted and sub-
jected to Western blotting as described in Section 2. 
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location in dying WIL-2 cells is initiated by the appearance of 
the DNA damage [27]. Alternatively, it should be considered 
as a cell cycle-independent consequence of an apoptotic path-
way realization. At present it is hard to say what step(s) in the 
Fas-mediated signal pathway is (are) cell cycle dependent. Be-
sides the p53 translocation and the following gene activation, 
the function of the proteins discovered recently should be also 
considered [28,29,31]. Taking into account the significance of 
kinase and phosphatase activities in the mechanism of cell 
cycle regulation [30], it is attractive to speculate on the phos-
phatase and kinase associated to Fas receptor [29,31] as a key 
factor linking the cell cycle mechanism and Fas-mediated 
apoptotic signalling. 
As a conclusion it should be noted that the results obtained 
can be extended to further study of the possible therapeutic 
potential of the combined treatment of Fas-bearing tumor 
cells with anti-Fas antibodies and cell cycle blocking agents. 
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